Yes, Stop the GLP-1 Receptor Agonist Immediately
For a patient recovering from gallstone pancreatitis and scheduled for cholecystectomy, you must stop the GLP-1 receptor agonist (e.g., semaglutide) immediately and hold it for at least three half-lives before surgery to minimize aspiration risk during anesthesia. 1
Why This Matters
GLP-1 receptor agonists significantly delay gastric emptying and increase the risk of retained gastric contents, regurgitation, and pulmonary aspiration during anesthesia—even with appropriate fasting. Multiple case reports document aspiration events in patients who stopped their GLP-1 RA 4-6 days before surgery, demonstrating that short interruptions are insufficient 1.
Your patient has two compounding risk factors:
- Recent gallstone pancreatitis (already indicates biliary/pancreatic pathology)
- Upcoming cholecystectomy requiring general anesthesia (high aspiration risk)
Notably, GLP-1 RAs are independently associated with increased risk of gallbladder disease, including cholelithiasis and cholecystitis, through mechanisms involving cholecystokinin suppression and bile stasis 2. One case report even documented a patient who developed acute gallstone pancreatitis while on semaglutide and required emergency cholecystectomy 3.
Specific Timing for Drug Cessation
Hold the GLP-1 RA for at least three half-lives before surgery to clear approximately 88% of the drug 1:
- Semaglutide (weekly): Stop 3 weeks (21 days) before surgery
- Dulaglutide (weekly): Stop 2 weeks (14 days) before surgery
- Liraglutide (daily): Stop 3-4 days before surgery
The 2024 Anaesthesia guidelines emphasize this is particularly critical for patients taking GLP-1 RAs for weight loss (where higher doses are used), though the same precautions apply for diabetes management 1.
Critical Caveat About Diabetes Management
If your patient has type 2 diabetes, consult endocrinology immediately regarding:
- Risks/benefits of the 3-week cessation period
- Bridging diabetic therapy during this interruption 1
The concern is that prolonged GLP-1 RA cessation may worsen perioperative glycemic control. However, in this specific case with recent pancreatitis and upcoming surgery, the aspiration risk clearly outweighs glycemic concerns—alternative diabetes medications can bridge this period.
Day-of-Surgery Aspiration Risk Mitigation
Even with appropriate drug cessation, implement these strategies 1:
- Extended fasting: Consider clear liquid diet for 24-48 hours before standard NPO times
- Gastric ultrasound: Use point-of-care ultrasound to assess residual gastric volume (target <1.5 mL/kg)
- Prokinetic agents: Consider metoclopramide or erythromycin preoperatively
- Airway management: Plan for rapid sequence intubation if gastric contents are concerning
- Document symptoms: Ask specifically about nausea, vomiting, or abdominal distention
Additional Considerations for This Patient
Given the recent pancreatitis, be aware that:
- GLP-1 RAs carry a small but increased risk of acute pancreatitis (HR 1.058) 4
- The risk is highest during early treatment phases (first 6 months) 4
- One case report documented concurrent DKA, acute pancreatitis, and ruptured acalculous cholecystitis in a patient on semaglutide 5
Do not restart the GLP-1 RA postoperatively until:
- Patient is eating and drinking normally (usually 24-48 hours post-op)
- No signs of biliary complications
- Consider whether continuation is appropriate given the gallstone pancreatitis history 2
Common Pitfall to Avoid
Do not assume standard fasting times are sufficient. Multiple case reports document aspiration in patients who fasted 10-20 hours but were still on GLP-1 therapy 1. The delayed gastric emptying effect persists well beyond standard fasting periods and requires the full 3-half-life washout.